NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $8.99 +0.20 (+2.22%) Closing price 03:59 PM EasternExtended Trading$8.99 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Verastem Stock (NASDAQ:VSTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Verastem alerts:Sign Up Key Stats Today's Range$8.78▼$9.0750-Day Range$5.29▼$10.7752-Week Range$2.54▼$11.24Volume783,663 shsAverage Volume1.86 million shsMarket Capitalization$553.55 millionP/E RatioN/ADividend YieldN/APrice Target$13.29Consensus RatingBuy Company Overview Verastem Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept. The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes. Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment.AI Generated. May Contain Errors. Read More Verastem Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreVSTM MarketRank™: Verastem scored higher than 54% of companies evaluated by MarketBeat, and ranked 567th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialVerastem has a consensus price target of $13.29, representing about 48.0% upside from its current price of $8.98.Amount of Analyst CoverageVerastem has only been the subject of 4 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.02) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Verastem's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.46% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Verastem has recently increased by 5.39%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.46% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Verastem has recently increased by 5.39%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News SentimentN/A News SentimentVerastem has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.Search Interest26 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,055.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VSTM Stock News HeadlinesWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to HoldSeptember 22, 2025 | americanbankingnews.comTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16, 2025 | finance.yahoo.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.October 2 at 2:00 AM | Crypto 101 Media (Ad)Leerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comBalyasny Asset Management L.P. Increases Stake in Verastem IncAugust 20, 2025 | gurufocus.comSee More Headlines VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $5.17 at the beginning of the year. Since then, VSTM shares have increased by 73.6% and is now trading at $8.9750. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) posted its quarterly earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.25. The biopharmaceutical company had revenue of $2.14 million for the quarter, compared to analyst estimates of $6.01 million. Read the conference call transcript. When did Verastem's stock split? Shares of Verastem reverse split before market open on Thursday, June 1st 2023.The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Gilead Sciences (GILD). Company Calendar Last Earnings8/07/2025Today10/02/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Verastem$13.29 High Price Target$20.00 Low Price Target$8.00 Potential Upside/Downside+48.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.64 million Net MarginsN/A Pretax Margin-7,785.21% Return on EquityN/A Return on Assets-119.85% Debt Debt-to-Equity Ratio2.06 Current Ratio3.46 Quick Ratio3.44 Sales & Book Value Annual Sales$10 thousand Price / Sales55,176.76 Cash FlowN/A Price / Cash FlowN/A Book Value($0.65) per share Price / Book-13.79Miscellaneous Outstanding Shares61,540,000Free Float60,253,000Market Cap$551.77 million OptionableOptionable Beta0.90 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:VSTM) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.